Skip to main content
. 2023 May 1;22(2):114–123. doi: 10.1055/s-0043-1764306

Fig. 5.

Fig. 5

A 52-year-old male with incidentally detected hepatitis B virus-related hepatocellular carcinoma with portal vein thrombosis underwent Rhenium-188-N diethyldithiocarbamate lipiodol transarterial radionuclide therapy; the post-therapy whole-body planar imaging up to 72 hours showing localized retention of lipiodol in liver seg. II/III lesion, faint visualization of kidneys in 2 to 6 hours with maximum visualization in 24 to 48 hours, minimal small intestine tracer uptake over 12 to 24 hours, and high bladder uptake due urinary excretion.